SAN FRANCISCO, Aug.  05, 2026  (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other

BRVE

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

Braveheart Bio upsized IPO priced at $18, raising $382.5M

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN FRANCISCO, Aug.  05, 2026  (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Braveheart Bio priced an upsized IPO at $18 per share, selling 21.25 million shares and targeting roughly $382.5 million in gross proceeds. The underwriters have a 30-day option to sell up to 3.19 million additional shares. BRVE is set to trade on the Nasdaq Global Market starting August 6, 2026, with proceeds to advance its hypertrophic cardiomyopathy programs.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>BRVE upsized IPO priced at $18, 21,250,000 shares offered.</li><li>Underwriters hold a 30-day option for 3,187,500 additional shares.</li><li>Gross proceeds expected ~$382.5 million before fees and expenses.</li><li>Trading on Nasdaq Global Market expected Aug 6, 2026 under BRVE.</li><li>Lead candidate BHB-1893 targets obstructive/non-obstructive HCM with a CMI.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Braveheart Bio, Inc. (BRVE)</strong>: Upsized IPO and ultimate trading catalyst; dilution risk may affect early perf.</li><li><strong>Goldman Sachs &amp; Co. LLC (GS)</strong>: Joint book-running manager; key arbiter of initial float and pricing.</li><li><strong>Jefferies LLC (JEF)</strong>: Joint book-running manager; significant role in underwriting and allocations.</li><li><strong>TD Cowen (TD)</strong>: Joint book-running manager; underwriter involvement supports IPO execution.</li><li><strong>Stifel, Nicolaus &amp; Company (SF)</strong>: Joint book-running manager; underwriter presence in the syndicate.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article covers Braveheart Bio&#039;s IPO pricing and underwriter details, a primary capital-raising event that directly affects BRVE&#039;s capital structure and float dynamics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Upsized offering signals strong investor appetite for BRVE&#039;s HCM focus.</li><li>First trading day set for Aug 6, 2026 on Nasdaq Global Market BRVE.</li><li>Gross proceeds ~$382.5 million imply a new baseline market cap post-IPO.</li><li>Underwriters&#039; overallotment adds potential for further supply/dilution.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Shares offered: 21,250,000.</li><li>Underwriters&#039; option: up to 3,187,500 additional shares.</li><li>Offer price: $18.00 per share.</li><li>Gross proceeds: approximately $382.5 million (before discounts/expenses).</li><li>Expected trading start: Aug 6, 2026; closing date anticipated Aug 7, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term BRVE trades will hinge on IPO dynamics; upside depends on HCM program progress and early investor demand.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN FRANCISCO, Aug.  05, 2026  (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BRVE">BRVE</a>), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol "BRVE." The offering is expected to close on August 7, 2026, subject to the satisfaction of customary closing conditions. All shares of common stock are being offered by Braveheart Bio.</p>  <p>Braveheart Bio has granted the underwriters a 30-day option to purchase up to an additional 3,187,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.</p>  <p>The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock.</p>  <p>Goldman Sachs &amp; Co. LLC, Jefferies, TD Cowen, Stifel and Cantor are acting as joint book-running managers for the offering.</p>  <p>Registration statements relating to the shares being sold in the initial public offering have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on August 5, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Cantor Fitzgerald &amp; Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.</p>  <p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>  <p><strong>About Braveheart Bio</strong><br></br>Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.</p>  <p><strong>Forward-Looking Statements</strong><br></br>This press release contains forward-looking statements, including, without limitation, statements regarding the expected commencement of trading of Braveheart Bio’s common stock on the Nasdaq Global Market, the completion and timing of the closing of the initial public offering, the expected gross proceeds from the offering, and the potential exercise by the underwriters of their option to purchase additional shares.</p>  <p>Words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "should," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</p>  <p>Forward-looking statements are based on Braveheart Bio’s current expectations and assumptions. These statements are neither promises nor guarantees and involve risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks relating to the satisfaction of customary closing conditions, changes in market conditions and the other risks and uncertainties described under the heading "Risk Factors" in Braveheart Bio’s registration statement on Form S-1, as amended, and the final prospectus relating to the offering to be filed with the SEC.</p>  <p>Any forward-looking statements contained in this press release speak only as of the date of this press release. Except as required by applicable law, Braveheart Bio undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</p>  <p><strong>Investor Relations Contact</strong><br></br>Alexander Sharif<br></br>New Street Investor Relations<br></br>Alexander@NewStreetIR.com</p>  <p><strong>Media Contact</strong><br></br>FGS Global<br></br>Braveheart-bio@fgsglobal.com </p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNDkxOCM3NzYyNDQ4IzIzMTI1OTA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZWMzNjYwODktZDU1Yi00MDc5LTk0ZWEtZjA3Mzg1NDViZGI1LTEzMjQxNDAtMjAyNi0wOC0wNi1lbg==/tiny/Braveheart-Bio-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/7d124852-a695-4916-a0bf-6ff3051c9a0c"><img src="https://ml.globenewswire.com/media/7d124852-a695-4916-a0bf-6ff3051c9a0c/small/braveheartbio-logo-full-color-jpg.jpg" border="0" width="150" height="32" alt="Primary Logo"></img></a></p>

Braveheart Bio priced an upsized IPO at $18 per share, selling 21.25 million shares and targeting roughly $382.5 million in gross proceeds. The underwriters have a 30-day option to sell up to 3.19 million additional shares. BRVE is set to trade on the Nasdaq Global Market starting August 6, 2026, with proceeds to advance its hypertrophic cardiomyopathy programs.

News insight

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

AI summary

Sentiment rationale

Key facts

Corporate Developments